CorMedix (NASDAQ:CRMD - Get Free Report) is expected to issue its quarterly earnings data before the market opens on Tuesday, March 11th. Analysts expect the company to announce earnings of $0.05 per share and revenue of $27.46 million for the quarter.
CorMedix Trading Up 12.9 %
Shares of CorMedix stock traded up $1.22 on Friday, reaching $10.71. 1,575,745 shares of the stock were exchanged, compared to its average volume of 1,093,221. The business has a fifty day moving average price of $10.49 and a two-hundred day moving average price of $9.44. CorMedix has a 1-year low of $3.03 and a 1-year high of $13.85. The firm has a market capitalization of $649.85 million, a PE ratio of -13.22 and a beta of 1.53.
Wall Street Analyst Weigh In
Several research firms have weighed in on CRMD. Royal Bank of Canada raised their target price on shares of CorMedix from $11.00 to $12.00 and gave the company an "outperform" rating in a report on Thursday, December 19th. Leerink Partners began coverage on CorMedix in a report on Friday. They set an "outperform" rating and a $18.00 target price on the stock. StockNews.com raised CorMedix to a "sell" rating in a research note on Friday, November 8th. Finally, D. Boral Capital reissued a "buy" rating and set a $15.00 price target on shares of CorMedix in a research note on Wednesday. One equities research analyst has rated the stock with a sell rating and seven have given a buy rating to the company. According to data from MarketBeat, CorMedix presently has an average rating of "Moderate Buy" and an average price target of $16.00.
Get Our Latest Analysis on CorMedix
CorMedix Company Profile
(
Get Free Report)
CorMedix Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.
Recommended Stories
Before you consider CorMedix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CorMedix wasn't on the list.
While CorMedix currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
